欢迎来到天天文库
浏览记录
ID:55744219
大小:486.54 KB
页数:6页
时间:2020-06-06
《心脉隆注射液治疗慢性心力衰竭临床疗效的Meta分析.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、·1388··医学循证·心脉隆注射液治疗慢性心力衰竭临床疗效的Meta分析张家关,尚亚东,吴晓蓉,傅英杰,谢春毅【摘要】目的评价心脉隆注射液治疗慢性心力衰竭的临床疗效和安全性。方法计算机检索中国知网(CNKI)、中国生物医学文献光盘数据库(CBMdisk)、维普中文科技期刊数据库(VIP)、PubMed及Cochranelibrary有关常规治疗基础上加用心脉隆注射液治疗慢性心力衰竭的研究。采用RevMan5.2.4软件对各项研究的B型脑钠肽(BNP)水平、心脏超声指标[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心
2、室舒张末期内径(LVEDD)]、6min步行距离(6一MWD)、中心静脉压(CVP)、临床疗效等进行分析。结果共纳入8个随机对照试验,共计866例心力衰竭患者,文献质量偏低。Meta分析显示,在心力衰竭患者常规治疗的基础上加入心脉隆注射液后,能够进一步降低BNP水平[加权均数差(WMD):87.46,95%C/(74.90,100.03)]和CVP[WMD=0.78,95%C/(0.33,1.24)],增加LVEF[WMD:6.58,95%CI(4.89,8.27)]和6一MWD[WMD=52.86,95%C/(38.o4,67.68)
3、],提高临床疗效[OR=3.00,95%C/(1.79,5.02)],还能改善远期复合终点和血清尿酸水平(P4、4,17(12):1388—1393.[w3~cw.chinagp.net]ClinialEficacyofXinmailonglrOeetionintheTreatmentofChronicHeartFailure:AMetaAnalysisZHANGJia—mei,SHANGYa—d0,,uXiao—rong,eta1.DepartmentofCardiology,ShanghaiTCM—IntegratedHo~ital,Shanghai200082,China【Abstract】OMectiveToevaluatetheclin5、icaleficacyandsafetyofXinmailonginjectioninthetreatmentofchronicheartfailure.MethodsWesearchedintheCNKI,CBMdisk,VIP,PubMedandCochranelibrarytoidentifystudiesontheclinicaleficacyandsafetyofXinmailonginjectioninthetreatmentofchronicheartfailurebasedonconventionaltherapy.Th6、eBNPlevel,heartultrasonicparametem[1eftventricularejectionfraction(LVEF),leftventricularendsystolicdiameter(LVESD),leftventricularenddiastolicdiameter(LVEDD)],6minwalkingdistance(6一MWD),centralvenouspressure(cvp)andclinicaleficacyofstudieswereanalyzedbytheRevMan5.2.4soft7、ware.ResultsAtotalof8randomizedcontrolledtrimswerereviewed,and866patientswereincluded,theliteraturequalitywasrelativelow.Metaanalysisresultshowedthat:forpatientswithheartfailurewhoreceivedXinmailonginjectiontreatmentonthebasisofconventionaltherapy,BNPlevel(WMD=87.46,95%C8、I(74.90,100.03)]andCVP[WMD:0.78,95%C/(0.33,1.24)]decreasedsignificantly,LVEF[WMD=6.58,95%C/(4.89,8.27)]
4、4,17(12):1388—1393.[w3~cw.chinagp.net]ClinialEficacyofXinmailonglrOeetionintheTreatmentofChronicHeartFailure:AMetaAnalysisZHANGJia—mei,SHANGYa—d0,,uXiao—rong,eta1.DepartmentofCardiology,ShanghaiTCM—IntegratedHo~ital,Shanghai200082,China【Abstract】OMectiveToevaluatetheclin
5、icaleficacyandsafetyofXinmailonginjectioninthetreatmentofchronicheartfailure.MethodsWesearchedintheCNKI,CBMdisk,VIP,PubMedandCochranelibrarytoidentifystudiesontheclinicaleficacyandsafetyofXinmailonginjectioninthetreatmentofchronicheartfailurebasedonconventionaltherapy.Th
6、eBNPlevel,heartultrasonicparametem[1eftventricularejectionfraction(LVEF),leftventricularendsystolicdiameter(LVESD),leftventricularenddiastolicdiameter(LVEDD)],6minwalkingdistance(6一MWD),centralvenouspressure(cvp)andclinicaleficacyofstudieswereanalyzedbytheRevMan5.2.4soft
7、ware.ResultsAtotalof8randomizedcontrolledtrimswerereviewed,and866patientswereincluded,theliteraturequalitywasrelativelow.Metaanalysisresultshowedthat:forpatientswithheartfailurewhoreceivedXinmailonginjectiontreatmentonthebasisofconventionaltherapy,BNPlevel(WMD=87.46,95%C
8、I(74.90,100.03)]andCVP[WMD:0.78,95%C/(0.33,1.24)]decreasedsignificantly,LVEF[WMD=6.58,95%C/(4.89,8.27)]
此文档下载收益归作者所有